FRANKFURT, March 9 (Reuters) - Shares in Roche dropped more than 5% on Monday as the Swiss drugmaker failed to show that its ...
A phase 3 trial of Roche’s giredestrant in first-line breast cancer patients has missed its primary endpoint, tarnishing the record of a drug that hit the mark in adjuvant and second-line settings.
The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...
AstraZeneca has also filed an oral SERD, camizestrant, targeting use of the drug in patients with advanced HR-positive breast ...
A phase III trial found that combining giredestrant with Pfizer’s Ibrance did not significantly slow disease progression compared with standard ...
FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann/File Photo LONDON, Dec 10 (Reuters) - Roche said on Wednesday ...
The FDA will end a roughly nine-month hiatus of drug-related advisory committee meetings, with plans to convene its first session of 2026 to scrutinize a pair of oncology applications from AstraZen | ...
Smart pill bottles may boost adherence to oral breast cancer therapies through daily reminders and tracking, though cost and technology barriers remain, says Steven Manobianco, MD. I think that the ...
Roche said the late-stage trial did not provide reliable evidence that the drug's use in combination with Pfizer's Ibrance ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results